IL165950A0 - Compositions and method for the diagnosis and treatment of tumor - Google Patents
Compositions and method for the diagnosis and treatment of tumorInfo
- Publication number
- IL165950A0 IL165950A0 IL16595004A IL16595004A IL165950A0 IL 165950 A0 IL165950 A0 IL 165950A0 IL 16595004 A IL16595004 A IL 16595004A IL 16595004 A IL16595004 A IL 16595004A IL 165950 A0 IL165950 A0 IL 165950A0
- Authority
- IL
- Israel
- Prior art keywords
- tumor
- diagnosis
- compositions
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Testing Resistance To Weather, Investigating Materials By Mechanical Methods (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39499802P | 2002-07-09 | 2002-07-09 | |
PCT/US2003/021606 WO2004004662A2 (fr) | 2002-07-09 | 2003-07-08 | Compositions et méthodes de diagnostic et de traitement de tumeurs |
Publications (1)
Publication Number | Publication Date |
---|---|
IL165950A0 true IL165950A0 (en) | 2006-01-15 |
Family
ID=30115799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16595004A IL165950A0 (en) | 2002-07-09 | 2004-12-23 | Compositions and method for the diagnosis and treatment of tumor |
Country Status (7)
Country | Link |
---|---|
US (2) | US20060062727A1 (fr) |
EP (1) | EP1572091A4 (fr) |
JP (1) | JP2006500009A (fr) |
AU (1) | AU2003249014B2 (fr) |
CA (1) | CA2491488A1 (fr) |
IL (1) | IL165950A0 (fr) |
WO (1) | WO2004004662A2 (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
CN1237076C (zh) | 1999-01-15 | 2006-01-18 | 杰南技术公司 | 具有改变的效应功能的多肽变体 |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
DK2345671T3 (en) * | 2002-09-27 | 2016-02-15 | Xencor Inc | Optimized Fc variants and methods for their formation |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
KR101019525B1 (ko) | 2004-11-12 | 2011-03-07 | 젠코어 인코포레이티드 | FcRn에 대한 변경된 결합성을 갖는 Fc 변이체 |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
DK1931709T3 (en) | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
CA2625998C (fr) | 2005-10-06 | 2015-12-01 | Xencor, Inc. | Anticorps anti-cd30 optimises |
DK2383297T5 (da) | 2006-08-14 | 2022-07-04 | Xencor Inc | Optimerede antistoffer rettet mod CD19 |
JP5562031B2 (ja) | 2006-09-18 | 2014-07-30 | ゼンコー・インコーポレイテッド | Hm1.24を標的とする最適化抗体 |
ES2532461T3 (es) | 2007-12-26 | 2015-03-27 | Xencor, Inc. | Variantes de FC con enlazamiento alterado a FCRN |
BRPI0907237A2 (pt) * | 2008-01-11 | 2015-07-14 | Univ Tokyo | Anticorpo anti-cldn6 |
WO2011028952A1 (fr) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes |
WO2011091078A2 (fr) | 2010-01-19 | 2011-07-28 | Xencor, Inc. | Variants d'anticorps possédant une activité complémentaire accrue |
JP5926791B2 (ja) | 2011-03-29 | 2016-05-25 | ロシュ グリクアート アーゲー | 抗体Fc変種 |
AU2013288641B2 (en) | 2012-07-13 | 2017-07-06 | Roche Glycart Ag | Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases |
BR112019001989A2 (pt) | 2016-08-02 | 2019-08-20 | Visterra Inc | polipeptídeos projetados e usos dos mesmos |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU674568B2 (en) * | 1993-02-04 | 1997-01-02 | Anaphore, Inc. | Improved method for the refolding of proteins |
IT1318691B1 (it) * | 2000-09-12 | 2003-08-27 | Consiglio Nazionale Ricerche | Varianti di proteine allergeniche del gruppo 2 di dermatophagoides. |
WO2003086307A2 (fr) * | 2002-04-12 | 2003-10-23 | The Board Of Trustees Of The University Of Arkansas | ?2-microglobiline (?2m) et agents de liaison anti-?2m utilises comme agents therapeutiques anticancereux |
-
2003
- 2003-07-08 US US10/521,053 patent/US20060062727A1/en not_active Abandoned
- 2003-07-08 EP EP03763455A patent/EP1572091A4/fr not_active Withdrawn
- 2003-07-08 CA CA002491488A patent/CA2491488A1/fr not_active Abandoned
- 2003-07-08 JP JP2004520117A patent/JP2006500009A/ja not_active Withdrawn
- 2003-07-08 WO PCT/US2003/021606 patent/WO2004004662A2/fr active Search and Examination
- 2003-07-08 AU AU2003249014A patent/AU2003249014B2/en not_active Expired - Fee Related
-
2004
- 2004-12-23 IL IL16595004A patent/IL165950A0/xx unknown
-
2006
- 2006-09-29 US US11/537,292 patent/US20090181014A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2004004662A2 (fr) | 2004-01-15 |
EP1572091A2 (fr) | 2005-09-14 |
AU2003249014B2 (en) | 2009-07-02 |
CA2491488A1 (fr) | 2004-01-15 |
AU2003249014A1 (en) | 2004-01-23 |
WO2004004662A3 (fr) | 2005-08-11 |
US20060062727A1 (en) | 2006-03-23 |
EP1572091A4 (fr) | 2008-03-05 |
US20090181014A1 (en) | 2009-07-16 |
JP2006500009A (ja) | 2006-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1571968A4 (fr) | Compositions et methodes permettant de diagnostiquer et de traiter une tumeur | |
EP1589933A4 (fr) | Compositions et methodes pour le diagnostic et le traitement d'une tumeur | |
IL165950A0 (en) | Compositions and method for the diagnosis and treatment of tumor | |
EP1578996A4 (fr) | Compositions et methodes pour diagnostiquer et traiter des tumeurs | |
EP1553912A4 (fr) | Compositions et methodes pour le diagnostic et pour le traitement d'une tumeur | |
WO2004030615A8 (fr) | Compositions et procedes de diagnostic et de traitement de tumeur | |
WO2004016225A8 (fr) | Compositions et methodes de diagnostic et de traitement des tumeurs | |
EP1571968A3 (fr) | Compositions et methodes permettant de diagnostiquer et de traiter une tumeur | |
EP1575571A4 (fr) | Compositions et methodes de diagnostic et de traitement d'une tumeur | |
EP1572091A3 (fr) | Compositions et methodes de diagnostic et de traitement de tumeurs | |
EP1575480A4 (fr) | Compositions et methodes de traitement de maladies relatives au systeme immunitaire | |
EP1578367A4 (fr) | Compositions et methodes pour le traitement de maladies liees au systeme immunitaire | |
EP1572116A4 (fr) | Compositions et procedes destines au traitement de maladies de nature immune | |
EP1576137A4 (fr) | Compositions et methodes de traitement de maladies liees au systeme immunitaire | |
AU2003302892A8 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
EP1416961A4 (fr) | Composition et procede pour le traitement d'une maladie | |
HK1086488A1 (en) | Compound and use thereof for the treatment of cancer | |
IL162201A0 (en) | New methods for diagnosis and treatment of tumours | |
AU2003300368A8 (en) | Methods and compositions for the diagnosis, prognosis, and treatment of cancer | |
AU2003290605A8 (en) | Compositions and methods for the diagnosis and treatment of sepsis | |
ZA200301204B (en) | Compositions and methods for the diagnosis and treatment of tumor | |
ZA200510282B (en) | Compositions and methods for the diagnosis and treatment of tumor | |
AU8678501A (en) | Compositions and methods for the diagnosis and treatment of tumor | |
AU2003291536A8 (en) | Method for the diagnosis and treatment of vascular disease | |
IL165839A0 (en) | Compounds useful for the treatment of cancer compositions thereof and methods therewith |